LeMaitre Vascular - LMAT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $94.57
  • Forecasted Upside: -8.57%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$103.44
▼ -0.3 (-0.29%)

This chart shows the closing price for LMAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LeMaitre Vascular Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMAT

Analyst Price Target is $94.57
▼ -8.57% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for LeMaitre Vascular in the last 3 months. The average price target is $94.57, with a high forecast of $105.00 and a low forecast of $75.00. The average price target represents a -8.57% upside from the last price of $103.44.

This chart shows the closing price for LMAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in LeMaitre Vascular. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/24/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/22/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/21/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$90.00 ➝ $93.00
11/1/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$92.00 ➝ $93.00
10/15/2024Cantor FitzgeraldInitiated CoverageNeutral$96.00
9/20/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$92.00 ➝ $92.00
8/20/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$77.00 ➝ $100.00
8/2/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$79.00 ➝ $92.00
8/2/2024Lake Street CapitalInitiated CoverageBuy$85.00 ➝ $105.00
5/31/2024Roth CapitalUpgradeStrong-Buy
5/31/2024Roth MkmReiterated RatingBuy$100.00
5/3/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $77.00
5/3/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$69.00 ➝ $79.00
4/26/2024Stifel NicolausUpgradeHold ➝ Buy$59.00 ➝ $75.00
2/28/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$66.00 ➝ $69.00
2/6/2024KeyCorpInitiated CoverageSector Weight
10/23/2023JMP SecuritiesInitiated CoverageOutperform$60.00
9/5/2023OppenheimerInitiated CoverageOutperform$70.00
8/3/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$63.00 ➝ $67.00
8/2/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$62.00 ➝ $66.00
8/2/2023Lake Street CapitalBoost TargetBuy ➝ Buy$65.00 ➝ $75.00
5/3/2023Barrington ResearchUpgradeMarket Perform ➝ Outperform$62.00
3/7/2023Roth CapitalReiterated RatingNeutral
10/28/2022Barrington ResearchDowngradeOutperform ➝ Market Perform
4/29/2022Barrington ResearchLower Target$54.00 ➝ $50.00
2/25/2022Barrington ResearchLower Target$62.00 ➝ $54.00
9/16/2021Jefferies Financial GroupInitiated CoverageBuy$70.00
8/3/2021Roth CapitalBoost TargetNeutral$55.00 ➝ $58.00
7/30/2021Barrington ResearchBoost TargetOutperform$59.00 ➝ $64.00
5/4/2021Roth CapitalBoost TargetNeutral$53.00 ➝ $55.00
4/30/2021Lake Street CapitalBoost TargetBuy$55.00 ➝ $65.00
4/30/2021Barrington ResearchBoost TargetMarket Perform ➝ Outperform$49.00 ➝ $59.00
3/2/2021Roth CapitalReiterated RatingNeutral
2/26/2021Barrington ResearchBoost TargetOutperform$47.00 ➝ $49.00
2/12/2021KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
10/30/2020Roth CapitalBoost TargetNeutral$32.00 ➝ $36.00
10/30/2020Barrington ResearchBoost TargetOutperform$36.00 ➝ $46.00
7/24/2020Stifel NicolausBoost TargetHold$25.00 ➝ $30.00
7/24/2020Lake Street CapitalBoost TargetBuy$33.00 ➝ $38.00
5/4/2020Stifel NicolausLower TargetHold$30.00 ➝ $25.00
5/4/2020Roth CapitalLower TargetNeutral$32.50 ➝ $28.00
5/1/2020Barrington ResearchLower TargetOutperform$38.00 ➝ $32.00
4/8/2020SidotiLower TargetBuy$38.00 ➝ $34.00
4/6/2020Lake Street CapitalLower TargetBuy$40.00 ➝ $28.00
3/16/2020SidotiUpgradeNeutral ➝ Buy$38.00
2/24/2020Roth CapitalReiterated RatingNeutral
2/7/2020Barrington ResearchReiterated RatingBuy$38.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024
  • 13 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/23/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2024
  • 19 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/22/2024
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2024
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2024
  • 15 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2024

Current Sentiment

  • 15 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
LeMaitre Vascular logo
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $103.44
Low: $102.98
High: $104.11

50 Day Range

MA: $92.80
Low: $85.64
High: $105.50

52 Week Range

Now: $103.44
Low: $51.70
High: $106.49

Volume

97,400 shs

Average Volume

123,983 shs

Market Capitalization

$2.33 billion

P/E Ratio

56.52

Dividend Yield

0.62%

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of LeMaitre Vascular?

The following sell-side analysts have issued stock ratings on LeMaitre Vascular in the last twelve months: Barrington Research, Cantor Fitzgerald, JMP Securities, KeyCorp, Lake Street Capital, Oppenheimer Holdings Inc., Roth Capital, Roth Mkm, Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for LMAT.

What is the current price target for LeMaitre Vascular?

0 Wall Street analysts have set twelve-month price targets for LeMaitre Vascular in the last year. Their average twelve-month price target is $94.57, suggesting a possible downside of 8.6%. Lake Street Capital has the highest price target set, predicting LMAT will reach $105.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $75.00 for LeMaitre Vascular in the next year.
View the latest price targets for LMAT.

What is the current consensus analyst rating for LeMaitre Vascular?

LeMaitre Vascular currently has 2 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LMAT.

What other companies compete with LeMaitre Vascular?

Other companies that are similar to LeMaitre Vascular include Cardiovascular Systems, CryoLife, Vapotherm, Penumbra and Teleflex. Learn More about companies similar to LeMaitre Vascular.

How do I contact LeMaitre Vascular's investor relations team?

LeMaitre Vascular's physical mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier's listed phone number is (781) 221-2266. The official website for LeMaitre Vascular is www.lemaitre.com. Learn More about contacing LeMaitre Vascular investor relations.